Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2) - Concepedia

Concepedia

Publication | Open Access

Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)

DOI Full Paper Access

59

Citations

11

References

2021

Year

H. James Wedner, Emel Aygören‐Pürsün, Jonathan A. Bernstein, Timothy Craig, Richard Gower, Joshua Jacobs, Douglas Johnston, William R. Lumry, Bruce L. Zuraw, Jessica Best,

The Journal of Allergy and Clinical Immunology In Practice

Abstract

The safety, tolerability, and effectiveness of berotralstat were maintained over 48 weeks of treatment.

References

	Year	Citations

Page 1